Abstract
Due to their role in cellular signaling mitogen activated protein (MAP) kinases represent targets of pharmaceutical interest. However, the majority of known MAP kinase inhibitors compete with cellular ATP and target an ATP binding pocket that is highly conserved in the 500 plus representatives of the human protein kinase family. Here we review progress toward the development of non-ATP competitive MAP kinase inhibitors for the extracellular signal regulated kinases (ERK1/2), the c-jun N-terminal kinases (JNK1/2/3) and the p38 MAPKs (α, β, γ, and δ). Special emphasis is placed on the role of computational methods in the drug discovery process for MAP kinases. Topics include recent advances in X-ray crystallography theory that improve the MAP kinase structures essential to structurebased drug discovery, the use of molecular dynamics to understand the conformational heterogeneity of the activation loop and inhibitors discovered by virtual screening. The impact of an advanced polarizable force field such as AMOEBA used in conjunction with sophisticated kinetic and thermodynamic simulation methods is also discussed.
Keywords: Kinases, MAP, modeling, dynamics, non-ATP, inhibitor
Current Pharmaceutical Design
Title: Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Volume: 18 Issue: 9
Author(s): Michael J. Schnieders, Tamer S. Kaoud, Chunli Yan, Kevin N. Dalby and Pengyu Ren
Affiliation:
Keywords: Kinases, MAP, modeling, dynamics, non-ATP, inhibitor
Abstract: Due to their role in cellular signaling mitogen activated protein (MAP) kinases represent targets of pharmaceutical interest. However, the majority of known MAP kinase inhibitors compete with cellular ATP and target an ATP binding pocket that is highly conserved in the 500 plus representatives of the human protein kinase family. Here we review progress toward the development of non-ATP competitive MAP kinase inhibitors for the extracellular signal regulated kinases (ERK1/2), the c-jun N-terminal kinases (JNK1/2/3) and the p38 MAPKs (α, β, γ, and δ). Special emphasis is placed on the role of computational methods in the drug discovery process for MAP kinases. Topics include recent advances in X-ray crystallography theory that improve the MAP kinase structures essential to structurebased drug discovery, the use of molecular dynamics to understand the conformational heterogeneity of the activation loop and inhibitors discovered by virtual screening. The impact of an advanced polarizable force field such as AMOEBA used in conjunction with sophisticated kinetic and thermodynamic simulation methods is also discussed.
Export Options
About this article
Cite this article as:
J. Schnieders Michael, S. Kaoud Tamer, Yan Chunli, N. Dalby Kevin and Ren Pengyu, Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases, Current Pharmaceutical Design 2012; 18 (9) . https://dx.doi.org/10.2174/138161212799436368
DOI https://dx.doi.org/10.2174/138161212799436368 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews Future of Spermatogonial Stem Cell Culture: Application of Nanofiber Scaffolds
Current Stem Cell Research & Therapy The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Uric Acid and Hypertension
Current Pharmaceutical Design Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
Current Pharmaceutical Design Pulmonary Arterial Hypertension
Current Vascular Pharmacology Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line
Letters in Drug Design & Discovery Occurrence and Biological Properties of Sphingolipids - A Review
Current Nutrition & Food Science Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Cannabinoid Type 2 Receptor as a Target for Chronic - Pain
Mini-Reviews in Medicinal Chemistry Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
Recent Patents on Inflammation & Allergy Drug Discovery